CO2019010860A2 - Una formulación líquida de anticuerpo contra tnf alfa - Google Patents

Una formulación líquida de anticuerpo contra tnf alfa

Info

Publication number: CO2019010860A2
Authority: CO; Colombia
Prior art keywords: liquid formulation; antibody against; tnf alpha; against tnf; alpha
Prior art date: 2017-03-16

Application number

CONC2019/0010860A

Other languages

English (en)

Spanish (es)

Inventor

Sora Yun

Youn Kyung Ko

Jin Eon So

Original Assignee

Lg Chemical Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-03-16

Filing date

2019-09-30

Publication date

2020-01-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63522490&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2019010860(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2019-09-30 Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd

2020-01-17 Publication of CO2019010860A2 publication Critical patent/CO2019010860A2/es

Links

239000012669 liquid formulation Substances 0.000 title abstract 3
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
229960002964 adalimumab Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4231—Cytokines
- A61K40/4232—Tumor necrosis factors [TNF] or CD70
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Microbiology (AREA)
Mycology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Endocrinology (AREA)
Peptides Or Proteins (AREA)

CONC2019/0010860A 2017-03-16 2019-09-30 Una formulación líquida de anticuerpo contra tnf alfa CO2019010860A2 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
KR20170033188		2017-03-16
PCT/KR2018/003097 WO2018169348A1 (fr)	2017-03-16	2018-03-16	Formulation liquide d'anticorps anti-tnf alpha

Publications (1)

Publication Number	Publication Date
CO2019010860A2 true CO2019010860A2 (es)	2020-01-17

Family

ID=63522490

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CONC2019/0010860A CO2019010860A2 (es)	2017-03-16	2019-09-30	Una formulación líquida de anticuerpo contra tnf alfa

Country Status (14)

Country	Link
JP (2)	JP7109849B2 (fr)
KR (2)	KR20180106974A (fr)
CN (1)	CN110621303A (fr)
AU (1)	AU2018236651B2 (fr)
CO (1)	CO2019010860A2 (fr)
MA (1)	MA46988A1 (fr)
MX (1)	MX2019010895A (fr)
MY (1)	MY197202A (fr)
NZ (1)	NZ757965A (fr)
PH (1)	PH12019502075A1 (fr)
RU (1)	RU2756619C2 (fr)
UA (1)	UA123847C2 (fr)
WO (1)	WO2018169348A1 (fr)
ZA (1)	ZA201906696B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2021009851A (es) *	2019-02-18	2021-09-10	Lilly Co Eli	Formulacion de anticuerpos terapeuticos.
US20230203147A1 (en) *	2019-03-18	2023-06-29	Alvotech Hf	Aqueous formulations of tnf-alpha antibodies in high concentrations
TWI861073B (zh) *	2019-03-21	2024-11-11	美商再生元醫藥公司	含有抗il-33抗體之穩定調配物
WO2021164717A1 (fr) *	2020-02-20	2021-08-26	百奥泰生物制药股份有限公司	PRÉPARATION D'ANTICORPS ANTI-TNF-α, SA MÉTHODE DE PRÉPARATION ET SON UTILISATION
CA3187322A1 (fr) *	2020-07-13	2022-01-20	Merck Patent Gmbh	Excipients reducteurs de viscosite et leurs combinaisons pour formulations de proteines hautement concentrees

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX344727B (es) *	2010-11-11	2017-01-05	Abbvie Biotechnology Ltd	Formulaciones liquidas de anticuerpos anti-tnf-alfa de alta concentracion mejoradas.
UY34105A (es) *	2011-06-03	2012-07-31	Lg Life Sciences Ltd	Formulación líquida estable de etanercept
SG11201405475UA (en) *	2012-03-07	2014-10-30	Cadila Healthcare Ltd	Pharmaceutical formulations of tnf-alpha antibodies
MX2015003007A (es) *	2012-09-07	2015-06-05	Coherus Biosciences Inc	Formulaciones acuosas estables de adalimumab.
AU2014209994B2 (en)	2013-01-24	2017-03-16	Glaxosmithkline Intellectual Property Development Limited	TNF-alpha antigen-binding proteins
CA2906101A1 (fr)	2013-03-15	2014-09-18	Bayer Healthcare Llc	Formulations d'anticorps anti-recepteurs de prolactine
US20150274819A1 (en)	2014-03-03	2015-10-01	La Jolla Biologics, Inc.	Stable aqueous recombinant protein formulations
US10688187B2 (en)	2014-04-02	2020-06-23	Intas Pharmaceuticals Ltd.	Liquid pharmaceutical composition of adalimumab
ES2600488T3 (es) *	2014-05-23	2017-02-09	Ares Trading S.A.	Composición farmacéutica líquida
US9821059B2 (en)	2014-10-17	2017-11-21	Alteogen Inc.	Composition for stabilizing protein and pharmaceutical formulation comprising the same
HUP1400510A1 (hu) *	2014-10-28	2016-05-30	Richter Gedeon Nyrt	Gyógyászati TNFalfa ellenes antitest készítmény
US20180016333A1 (en) *	2015-01-28	2018-01-18	Mabxience, S.A.	Pharmaceutical formulations for anti-tnf-alpha antibodies
WO2016162819A1 (fr) *	2015-04-07	2016-10-13	Lupin Limited	Composition pharmaceutique aqueuse stable d'anticorps anti-tnf alpha

2018
- 2018-03-16 MY MYPI2019005331A patent/MY197202A/en unknown
- 2018-03-16 KR KR1020180031016A patent/KR20180106974A/ko not_active Ceased
- 2018-03-16 MX MX2019010895A patent/MX2019010895A/es unknown
- 2018-03-16 JP JP2019551275A patent/JP7109849B2/ja active Active
- 2018-03-16 RU RU2019130728A patent/RU2756619C2/ru active
- 2018-03-16 UA UAA201909838A patent/UA123847C2/uk unknown
- 2018-03-16 WO PCT/KR2018/003097 patent/WO2018169348A1/fr not_active Ceased
- 2018-03-16 NZ NZ757965A patent/NZ757965A/en unknown
- 2018-03-16 AU AU2018236651A patent/AU2018236651B2/en active Active
- 2018-03-16 MA MA46988A patent/MA46988A1/fr unknown
- 2018-03-16 CN CN201880031705.6A patent/CN110621303A/zh active Pending
2019
- 2019-09-12 PH PH12019502075A patent/PH12019502075A1/en unknown
- 2019-09-30 CO CONC2019/0010860A patent/CO2019010860A2/es unknown
- 2019-10-10 ZA ZA2019/06696A patent/ZA201906696B/en unknown
2020
- 2020-08-05 KR KR1020200098144A patent/KR102342292B1/ko active Active
2022
- 2022-05-06 JP JP2022076654A patent/JP2022097600A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
AU2018236651B2 (en)	2020-12-10
JP2020510079A (ja)	2020-04-02
RU2019130728A3 (fr)	2021-04-16
AU2018236651A1 (en)	2019-10-31
NZ757965A (en)	2022-07-01
JP7109849B2 (ja)	2022-08-01
ZA201906696B (en)	2020-08-26
KR20180106974A (ko)	2018-10-01
KR20200096472A (ko)	2020-08-12
BR112019019162A2 (pt)	2020-04-14
CN110621303A (zh)	2019-12-27
UA123847C2 (uk)	2021-06-09
JP2022097600A (ja)	2022-06-30
MA46988A1 (fr)	2020-06-30
KR102342292B1 (ko)	2021-12-24
MY197202A (en)	2023-05-31
RU2019130728A (ru)	2021-04-16
RU2756619C2 (ru)	2021-10-04
PH12019502075A1 (en)	2020-09-14
WO2018169348A1 (fr)	2018-09-20
MX2019010895A (es)	2019-11-05

Publication	Publication Date	Title
CO2019010860A2 (es)	2020-01-17	Una formulación líquida de anticuerpo contra tnf alfa
CY1123358T1 (el)	2021-12-31	Υδατικο φαρμακευτικο σκευασμα που περιεχει αντισωμα αντι-pd-1 αβελουμαμπη
MX2018001398A (es)	2018-05-28	Anticuerpos monoclonales contra bcma.
EA201791029A1 (ru)	2017-12-29	Антитела против интерлейкина-33 и их применение
MY198059A (en)	2023-07-31	Anti-ox40 antibodies and their uses
CL2016002455A1 (es)	2017-08-11	Anticuerpos multiespecíficos.
BR112018074468A2 (pt)	2019-03-06	anticorpos anti-cd40 e suas utilizações
EP4461312A3 (fr)	2025-01-22	Anticorps anti-pro/myostatine latent et leurs utilisations
BR112017008666A2 (pt)	2018-01-30	anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
EA201691610A1 (ru)	2016-11-30	Анти-jagged1 антитела и способы применения
MX2021010460A (es)	2021-09-21	Metodo de tratamiento con tradipitant.
MX2018016362A (es)	2019-04-22	Formulaciones de anticuerpo anti-cd19.
CL2017002055A1 (es)	2018-05-18	Muestra de líquido
BR112018002382A8 (pt)	2022-12-06	Novos anticorpos anti-gvpi humano e usos dos mesmos
CL2017001957U1 (es)	2018-06-22	Almohadilla urinaria masculina.
EA201992027A1 (ru)	2020-02-25	Водный состав антитела против pd-l1
UY36107A (es)	2015-11-30	Composición microencapsulada inhibidora de la nitrificación
TWD192262S (zh)	2018-08-11	Infusion Pump
BR112016027455A2 (pt)	2017-10-17	moduladores ppar
EP4467565A3 (fr)	2025-03-12	Formulations d'anticorps anti-tnf alpha
EA201792266A1 (ru)	2018-02-28	Способ получения соединения на основе ртути, соединение на основе ртути, способы применения соединения на основе ртути и применения соединения на основе ртути
MA39411A (fr)	2016-03-24	Synthèse de l'énantiomère de la progestérone et ses intermédiaires
CL2017003414S1 (es)	2018-03-16	Hervidor solar
CL2016002351A1 (es)	2017-03-24	Composiciones detergentes líquidas que comprenden una alfa-amilasa
UA114603U (uk)	2017-03-10	Накісткова пластина для остеосинтезу з приливками та дротяним серкляжем